Omeros provides regulatory update on biologics license application for narsoplimab in the treatment of hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the u.s. food and drug administration (fda) notified the company that, as part of fda's ongoing review of the company's biologics license application (bla) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma), fda has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. fda stated tha
OMER Ratings Summary
OMER Quant Ranking